register free | resend password


PAREXEL Ranked A Top CRO In CenterWatch Global Investigative Site Relationship Survey

Company recognised for sponsor/site relationship quality

ID: 1496283
recent pressrelease next pressrelease

(businesspress24) - Company recognised for sponsor/site relationship quality

LONDON, April 3, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organisation, today announced that it was named a top contract research organisation (CRO) in the CenterWatch 2017 Global Investigative Site Relationship Survey. The survey recognises CROs that have high-quality working relationships with investigative sites.

The survey, published today in CenterWatch Monthly, polled over 1,300 global investigative sites on aspects of their relationships with CROs during the past two years. PAREXEL ranked among the top five highest-rated CROs for the overall quality of its direct working relationships with investigative sites. In particular, PAREXEL ranked high in categories such as professional and efficient administrative staff; professional, knowledgeable, and well-trained monitors; understanding of local regulatory/ethics issues; and conduct of clear study initiation visits and training.

“Across the industry, the relationship between CROs and sites has become more strategic. To address this need, we have developed a tailored approach that helps us foster long-term quality partnerships,” said Paul Evans, Corporate Vice President, Global Site Strategy, PAREXEL. “PAREXEL’s high ranking is a reflection of our commitment to our clients and their journeys to bring new treatments to patients in need.”

PAREXEL’s global Site Alliance Network is a significant component of the Company’s approach. The network is comprised of 300 sites with dedicated PAREXEL relationship managers. These individuals also work with key site management organisations (SMOs) to reach an additional 250 sites. The network includes strategic collaborations with Academic Research Organizations on two continents and managed relationships that extend beyond single studies.

PAREXEL continuously solicits feedback from site staff to enhance its support. This enables faster patient recruitment, evaluation, and enrollment in clinical trials. Additionally, the feedback ensures quality and fosters greater collaboration between PAREXEL and sites.



“We focus on simplifying trial execution for busy sites and their staff through our dedicated on-site clinical research associates, office-based monitors, and other support functions,” said Karen Chu, Corporate Vice President, Global Clinical Operations, PAREXEL. “The CenterWatch survey results are a testament to our focus on delivering effective and timely support for our sites and our clients.”

CenterWatch’s 2017 Global Investigative Site Relationship Survey was conducted online between October 2016 and January 2017. The survey included participation from principal investigators, study coordinators, and other clinical research professionals from 1,376 sites. More than 80 percent of the sites were from North America and Europe. The survey, first launched in 1997, uses an instrument to measure sponsor/site relationship quality based on input from representatives from sponsor and CRO companies and investigative sites.



More information:
http://www.realwire.com/releases/PAREXEL-Ranked-A-Top-CRO-In-CenterWatch-Global-Investigative



Keywords (optional):

parexel, centerwatch, cro, global-investigative-site-relationship-survey, quality,



Company information / Profile:

PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology, and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialisation continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 85 locations in 51 countries around the world, and had approximately 19,625 employees in the second quarter. For more information about PAREXEL International visit www.PAREXEL.com.

PressRelease by

Requests:



PressContact / Agency:

Charlotte Bass/ Ivelina Adzheva
OneChocolate for PAREXEL
Tel.: +44 (0)20 7437 0227
Email: parexel(at)onechocolatecomms.co.uk



published by: RealWire
print pressrelease  send to a friend  

Date: 04/03/2017 - 16:06
Language: English
News-ID 1496283
Character count: 3241
Kontakt-Informationen:
Firma: RealWire
Ansprechpartner: Fran Cator Feedback to businesspress24.com about Pressrelease-id:
Stadt: Lincoln
Telefon: 01522 883640

Meldungsart: bitte
Versandart: Veröffentlichung
Freigabedatum:
Comments:



Number of hits: 394

Linking-Tips:



Direct Link to this PressRelease:






We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease






All members: 8 861
Register today: 0
Register yesterday: 6
Members online: 0
Guests online: 35


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.

Categories:


[ more PressReleases ][ RSS-Feed ]